Synexus Acquires ClinPharm
Synexus has agreed to acquire Leipzig based ClinPharm and will complete the acquisition in January 2010. This deal will increase the number of Synexus’ Dedicated Research Centres to 26 in nine countries, strengthening its European reach.
Synexus is a multi-national company focused on the recruitment and running of clinical trials at its own Dedicated Research Centres. While it has a network of research centres in Central and Eastern Europe, this acquisition will add eight research centres in Germany. It will strengthen Synexus’ Central and Eastern Europe portfolio of centres in Poland, Hungary and Bulgaria with additional sites in Austria and Ukraine. Synexus now has research centres in Western, Central and Eastern Europe, South Africa and Asia.
The ClinPharm acquisition will increase Synexus’ total patient population reach to over 30 million patients; an increase of 50 per cent globally and 100 per cent across Europe. ClinPharm also brings considerable additional therapy area experience to Synexus.
"In order to keep pace with the market’s demands it is necessary for us to increase our infrastructure and patient reach. ClinPharm provided the ideal opportunity as they have considerable presence in Western, Central and Eastern Europe and also understand the way we work,” said Synexus Chief Executive Michael Fort.
The deal will be finalised in January 2010 after ClinPharm’s year end. ClinPharm’s founding CEO, Hans-Detlev Stahl MD, Ph.D. (Melb). F.R.A.C.P joins Synexus as European Medical Director.
“It was a natural fit to team up with Synexus. We know each other very well and our geographic coverage is totally complementary. Together we are much stronger and I look forward to helping the new company with further expansion which delivers real benefits to our clients in pharma,” said Dr Stahl.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
